{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:10:20Z","timestamp":1791868220707,"version":"4.3.4"},"reference-count":111,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T00:00:00Z","timestamp":1762041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jdiacomp.2025.109193","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T23:34:19Z","timestamp":1760571259000},"page":"109193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Criteria of frail older people with type 2 diabetes who are suitable for SGLT-2 inhibitors and GLP-1RA therapy"],"prefix":"10.1016","volume":"39","author":[{"given":"A.H.","family":"Abdelhafiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Siqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2025.109193_bb0005","article-title":"IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0010","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jdiacomp.2017.05.003","article-title":"Frailty and sarcopenia\u2014newly emerging and high impact complications of diabetes","volume":"31","author":"Sinclair","year":"2017","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0015","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/j.1532-5415.2012.04054.x","article-title":"Prevalence of frailty in community-dwelling older persons: a systematic review","volume":"60","author":"Collard","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107639","article-title":"Cardio-renal protection in older people with diabetes with frailty and medical comorbidities - a focus on the new hypoglycaemic therapy","volume":"34","author":"Abdelhafiz","year":"2020","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0025","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.2337\/dc24-S013","article-title":"13. Older adults: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0030","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3904\/kjim.2016.193","article-title":"Sarcopenia and sarcopenic obesity","volume":"31","author":"Choi","year":"2016","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0035","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.exger.2007.03.003","article-title":"Aging in adipocytes: potential impact of inherent, depot-specific mechanisms","volume":"42","author":"Cartwright","year":"2007","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0040","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41574-018-0062-9","article-title":"Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies","volume":"14","author":"Batsis","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0045","first-page":"1","article-title":"Linking epidemiology and molecular mechanisms in sarcopenic obesity in populations","volume":"14","author":"El Bizri","year":"2020","journal-title":"Proc Nutr Soc"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0050","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3390\/ijms21031010","article-title":"Targeting age-dependent functional and metabolic decline of human skeletal muscle: the geroprotective role of exercise, myokine IL-6, and vitamin D","volume":"21","author":"Crescioli","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0055","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/ijo.2008.25","article-title":"Increased visceral fat and decreased energy expenditure during the menopausal transition","volume":"32","author":"Lovejoy","year":"2008","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0060","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1365-2265.2005.02315.x","article-title":"The association of sex hormone levels with poor mobility, low muscle strength and incidence of falls among older men and women","volume":"63","author":"Schaap","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0065","first-page":"731","article-title":"Frailty: an emerging research and clinical paradigm-issues and controversies","volume":"62A","author":"Bergman","year":"2009","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0070","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1093\/gerona\/gls068","article-title":"The role of androgens and estrogens on healthy aging and longevity","volume":"67","author":"Horstman","year":"2012","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Writing group for the European working group on sarcopenia in older people 2 (EWGSOP2), and the extended group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0080","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1530\/JOE-15-0533","article-title":"Insulin resistance and sarcopenia: mechanistic links between common co-morbidities","volume":"229","author":"Cleasby","year":"2016","journal-title":"J Endocrinol"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0085","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4093\/dmj.2016.40.3.182","article-title":"Sarcopenia, frailty, and diabetes in older adults","volume":"40","author":"Jang","year":"2016","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108065","article-title":"Triad of impairment in older people with diabetes-reciprocal relations and clinical implications","volume":"161","author":"Abdelhafiz","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/metabo13020295","article-title":"Metabolic impact of frailty changes diabetes trajectory","volume":"13","author":"Sinclair","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0100","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/ggi.12805","article-title":"Diabetes mellitus, hypertension and frailty: a population-based, cross-sectional study of Mexican older adults","volume":"17","author":"Castrej\u00f3n-P\u00e9rez","year":"2017","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109085","article-title":"Low glycaemic state increases risk of frailty and functional decline in older people with type 2 diabetes mellitus - evidence from a systematic review","volume":"181","author":"Abdelhafiz","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2019.107492","article-title":"COhort of GEriatric nephrology in NTUH (COGENT) study group. Hypoglycemic episodes are associated with an increased risk of incident frailty among new onset diabetic patients","volume":"34","author":"Chao","year":"2020","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0115","first-page":"S62","article-title":"Frailty among Mexican community-dwelling elderly: a story told 11 years later","volume":"57","author":"Aguilar-Navarro","year":"2015","journal-title":"Mex Health Aging Study Salud P\u00fablica Mex"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0120","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/gerona\/glu057","article-title":"Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases","volume":"69","author":"Franceschi","year":"2014","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0125","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/ggi.14142","article-title":"Microvascular complications and frailty can predict adverse outcomes in older patients with diabetes","volume":"21","author":"Sable-Morita","year":"2021","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0130","doi-asserted-by":"crossref","DOI":"10.1038\/s43856-021-00029-9","article-title":"An analysis of frailty and multimorbidity in 20,566 UK Biobank participants with type 2 diabetes","author":"Hanlon","year":"2021","journal-title":"Commun Med"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0135","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrm2391","article-title":"Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes","volume":"9","author":"Guilherme","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0140","article-title":"Impact of aging on the strength of cardiovascular risk factors: a longitudinal study over 40 years","volume":"7","author":"Lind","year":"2018","journal-title":"J Am Hear Assoc"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0145","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.diabet.2008.08.006","article-title":"Cardiometabolic determinants of mortality in a geriatric population: is there a \u201creverse metabolic syndrome\u201d?","volume":"35","author":"Vischer","year":"2009","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0150","doi-asserted-by":"crossref","first-page":"262","DOI":"10.14336\/AD.2014.1022","article-title":"Low HbA1c and increased mortality risk-is frailty a confounding factor?","volume":"6","author":"Abdelhafiz","year":"2015","journal-title":"Aging Dis"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0155","first-page":"454","article-title":"The u-shaped relationship of traditional cardiovascular risk factors and adverse outcomes in later life","volume":"3","author":"Abdelhafiz","year":"2012","journal-title":"Aging Dis"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0160","first-page":"454","article-title":"The U-shaped relationship of traditional cardiovascular risk factors and adverse outcomes in later life","volume":"3","author":"Abdelhafiz","year":"2012","journal-title":"Aging Dis"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0165","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/00325481.2021.1942934","article-title":"Sarcopenic obesity as a determinant of cardiovascular disease risk in older people: a systematic review","volume":"133","author":"Evans","year":"2021","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnha.2024.100342","article-title":"Joint effects of physical frailty and traditional cardiovascular risk factor control on cardiovascular disease in patients with diabetes","volume":"28","author":"Li","year":"2024","journal-title":"J Nutr Health Aging"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0175","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.diabres.2013.05.014","article-title":"Serum adipocyte fatty acid-binding protein levels are independently associated with sarcopenic obesity","volume":"101","author":"Kim","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0180","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrendo.2012.49","article-title":"Muscles, exercise and obesity: skeletal muscle as a secretory organ","volume":"8","author":"Pedersen","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0185","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s12603-009-0084-z","article-title":"Sarcopenic-obesity and cardiovascular disease risk in the elderly","volume":"13","author":"Stephen","year":"2009","journal-title":"J Nutr Health Aging"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0190","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.clnu.2017.06.009","article-title":"Dynapenic obesity as an associated factor to lipid and glucose metabolism disorders and metabolic syndrome in older adults-findings from SABE study","volume":"37","author":"Alexandre","year":"2018","journal-title":"Clin Nutr"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0195","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jacc.2014.12.040","article-title":"Pre-frailty and risk of cardiovascular disease in elderly men and women: the Pro.V.A. study","volume":"65","author":"Sergi","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0200","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3390\/jcm9051367","article-title":"Kyoto-Kameoka Study Group. A U-Shaped relationship between the prevalence of frailty and body mass index in community-dwelling japanese older adults: The Kyoto-Kameoka Study","volume":"9","author":"Watanabe","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0205","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1525-139X.2010.00701.x","article-title":"Glycemic control and burnt-out diabetes in ESRD","volume":"23","author":"Kovesdy","year":"2010","journal-title":"Semin Dial"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0210","first-page":"197","article-title":"Can diabetes medication be reduced in elderly patients? An observational study of diabetes drug withdrawal in nursing home patients with tight glycaemic control","volume":"82","author":"Sjoblom","year":"2008","journal-title":"Dib Res Clin Pract"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0215","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/ijcp.12455","article-title":"Can hypoglycaemic medications be withdrawn in older people with type 2 diabetes?","volume":"68","author":"Abdelhafiz","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0220","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1749-6632.2000.tb06498.x","article-title":"Body composition in healthy aging","volume":"904","author":"Baumgartner","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0225","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/ageing\/25.5.386","article-title":"Evidence for a non-linear relationship between leg strength and gait speed","volume":"25","author":"Buchner","year":"1996","journal-title":"Age Ageing"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0230","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/ageing\/afw214","article-title":"Longitudinal associations between body composition, sarcopenic obesity and outcomes of frailty, disability, institutionalisation and mortality in community-dwelling older men: the concord health and ageing in men project","volume":"46","author":"Hirani","year":"2017","journal-title":"Age Ageing"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0235","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.nutres.2015.09.003","article-title":"Sarcopenia, sarcopenic obesity, and functional impairments in older adults: national health and nutrition examination surveys 1999-2004","volume":"35","author":"Batsis","year":"2015","journal-title":"Nutr Res"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010805","article-title":"Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: findings from the national health and nutrition examination survey III","volume":"5","author":"Srikanthan","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0245","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.archger.2012.09.007","article-title":"Body composition and its association with cardiometabolic risk factors in the elderly: a focus on sarcopenic obesity","volume":"56","author":"Chung","year":"2013","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0250","doi-asserted-by":"crossref","first-page":"187","DOI":"10.11005\/jbm.2018.25.3.187","article-title":"Association between sarcopenia, sarcopenic obesity, and chronic disease in Korean elderly","volume":"25","author":"Lim","year":"2018","journal-title":"J Bone Metab"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0255","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.exger.2009.08.008","article-title":"Frailty in the elderly is associated with insulin resistance of glucose metabolism in the postabsorptive state only in the presence of increased abdominal fat","volume":"44","author":"Goulet","year":"2009","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004553","article-title":"Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: an individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events","volume":"22","author":"Wightman","year":"2025","journal-title":"PLoS Med"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0265","doi-asserted-by":"crossref","DOI":"10.1093\/gerona\/glad181","article-title":"Efficacy and safety of Dapagliflozin in patients with chronic kidney disease across the spectrum of frailty","volume":"79","author":"Vart","year":"2024","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0270","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2215\/CJN.0000000000000498","article-title":"Frailty, multimorbidity, and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial","volume":"19","author":"Mayne","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0275","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.2337\/dc23-0671","article-title":"Comparative cardiovascular effectiveness and safety of SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors according to frailty in type 2 diabetes","volume":"46","author":"Kutz","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0280","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1161\/CIRCULATIONAHA.122.061754","article-title":"Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial","volume":"146","author":"Butt","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0285","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/M21-4776","article-title":"Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial","volume":"175","author":"Butt","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0290","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2666-7568(23)00032-6","article-title":"Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial","volume":"4","author":"Pratley","year":"2023","journal-title":"Lancet Healthy Longev"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0295","doi-asserted-by":"crossref","first-page":"118","DOI":"10.53986\/ibjm.2023.0023","article-title":"Safety of SGLT2 inhibitors in very elderly diabetic type 2 patients","volume":"3","author":"Baeza-Trinidad","year":"2023","journal-title":"Iberoam J Med"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106396","article-title":"SGLT2-inhibitors are effective and safe in the elderly: the SOLD study","volume":"183","author":"Lunati","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0305","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2337\/dc19-1476","article-title":"Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE-TIMI 58 study","volume":"43","author":"Cahn","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0310","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/ageing\/afz096","article-title":"Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME\u00ae trial","volume":"48","author":"Monteiro","year":"2019","journal-title":"Age Ageing"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0315","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/jgs.14028","article-title":"Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: a pooled analysis","volume":"64","author":"Sinclair","year":"2016","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0320","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in over weight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"Group UKPDS","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0325","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1001\/archinte.168.19.2070","article-title":"Cardiovascular outcomes in trials of oral diabetes medications: a systematic review","volume":"168","author":"Selvin","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0330","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1742-1241.2012.02911.x","article-title":"Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial","volume":"66","author":"Henry","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0335","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1007\/s13300-021-01176-x","article-title":"Effects of dapagliflozin compared with sitagliptin and metformin in drug-na\u00efve Japanese patients with type 2 diabetes: a 12-week, open-label, randomized, active-controlled trial","volume":"12","author":"Ito","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0340","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2337\/dc15-1736","article-title":"Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-na\u00efve type 2 diabetes","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0345","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.7326\/M21-2941","article-title":"First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a cost-effectiveness study","volume":"175","author":"Choi","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0350","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.48431","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of retinopathy in patients with type 2 diabetes","volume":"6","author":"Yen","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0355","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0360","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0365","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Harmony outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0370","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/eurheartj\/ehz853","article-title":"Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high\/high cardiovascular risk","volume":"41","author":"Marx","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1289643","article-title":"First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis","volume":"15","author":"Deng","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0380","article-title":"SGLT2 inhibitors vs. GLP-1 agonists to treat the heart, the kidneys and the brain","volume":"10","author":"Rolek","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0385","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12916-024-03483-z","article-title":"Long-term comparison of renal and metabolic outcomes after sodium\u2013glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes","volume":"22","author":"Sohn","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0390","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55524-w","article-title":"Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: a meta-analysis","volume":"9","author":"Castellana","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0395","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1111\/dom.14108","article-title":"Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta-analysis","volume":"22","author":"Mantsiou","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0400","article-title":"The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0405","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study","volume":"385","author":"Simms-Williams","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0410","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/dom.16078","article-title":"One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA","volume":"27","author":"Zhang","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0415","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12933-024-02192-4","article-title":"Effectiveness and safety of the combination of sodium\u2013glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies","volume":"23","author":"Ahmad","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0420","article-title":"Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0425","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1220516","article-title":"Relationship between sodium-glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"14","author":"Xia","year":"2023","journal-title":"Front Endocrinol (Lausanne)."},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0430","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1161\/HYPERTENSIONAHA.122.19586","article-title":"SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients","volume":"79","author":"Mone","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0435","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40520-015-0525-y","article-title":"Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study","volume":"28","author":"Perna","year":"2016","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0440","first-page":"407","article-title":"Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus","volume":"10","author":"Rondanelli","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0445","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3803\/EnM.2016.31.1.80","article-title":"Effects of short-term exenatide treatment on regional fat distribution, glycated hemoglobin levels, and aortic pulse wave velocity of obese type 2 diabetes mellitus patients","volume":"31","author":"Hong","year":"2016","journal-title":"Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0450","doi-asserted-by":"crossref","DOI":"10.2337\/db18-673-P","article-title":"Novel approach to sarcopenia in diabetic patients treated with GLP-1 receptor agonists (GLP-1RA)","volume":"67","author":"Ikejima","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0455","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2147\/DMSO.S425642","article-title":"GLP-1RA liraglutide and semaglutide improves obesity-induced muscle atrophy via SIRT1 pathway","volume":"16","author":"Xiang","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166770","article-title":"Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice","volume":"1869","author":"Iwai","year":"2023","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0465","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1191815","article-title":"Muscle fiber necroptosis in pathophysiology of idiopathic inflammatory myopathies and its potential as target of novel treatment strategy","volume":"14","author":"Kamiya","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0470","article-title":"Cardiovascular risk reduction in older people with type 2 diabetes mellitus-a comprehensive narrative review","volume":"211","author":"Hnynn","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0475","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3390\/diabetology3020028","article-title":"Insulin in frail, older people with type 2 diabetes\u2014low threshold for therapy","volume":"3","author":"Abdelhafiz","year":"2022","journal-title":"Diabetology"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0480","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1017\/S0007114511007422","article-title":"Resistance exercise enhances myofibrillar protein synthesis with graded intakes of whey protein in older men","volume":"108","author":"Yang","year":"2012","journal-title":"Br J Nutr"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0485","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jamda.2015.05.021","article-title":"Effects of a vitamin D and leucine enriched whey protein nutritional supplement on measures of sarcopenia in older adults, the PROVIDE study: a randomized, double-blind, placeobo-controlled trial","volume":"16","author":"Bauer","year":"2015","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0490","first-page":"542","article-title":"Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE study group","volume":"14","author":"Bauer","year":"2013","journal-title":"JAMDA"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0495","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7150\/ijms.4.19","article-title":"Strength training improves muscle quality and insulin sensitivity in Hispanic older adults with type 2 diabetes","volume":"4","author":"Brooks","year":"2007","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0500","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jamda.2012.05.020","article-title":"Protein supplementation increases muscle mass gain during prolonged resistance-type exercise training in frail elderly people: a randomized, double-blind, placebo controlled trial","volume":"13","author":"Tieland","year":"2012","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0505","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2023.1164469","article-title":"Eicosapentaenoic acid and branched-chain amino acids fortified complete nutrition drink improved muscle strength in older individuals with inadequate protein intake","volume":"10","author":"Khoonin","year":"2023","journal-title":"Front Nutr"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0510","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.exger.2013.11.002","article-title":"The combined effects of diet quality and physical activity on maintenance of muscle strength among diabetic older adults from the NuAge cohort","volume":"49","author":"Rahi","year":"2014","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0515","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0520","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0525","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of multifactorial intervention on mortality in Type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0530","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/metabo15010049","article-title":"The use of SGLT-2 inhibitors and GLP-1RA in frail older people with diabetes: a personalised approach is required","volume":"15","author":"Sinclair","year":"2025","journal-title":"Metabolites"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0535","first-page":"1","article-title":"De-escalation, palliation and end of life care in frail older people with diabetes-a critical review","author":"Siqueira","year":"2025","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0540","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13175325","article-title":"Frailty detection in older adults with diabetes: a scoping review of assessment tools and their link to key clinical outcomes","volume":"13","author":"Guevara","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0545","article-title":"Triglyceride-glucose index as a potential indicator of sarcopenic obesity in older people","volume":"15","author":"Kim","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0550","doi-asserted-by":"crossref","DOI":"10.1177\/23814683231187566","article-title":"Expected health benefits of SGLT-2 inhibitors and GLP-1 receptor agonists in older adults","volume":"8","author":"Dadwani","year":"2023","journal-title":"MDM Policy & Practice"},{"key":"10.1016\/j.jdiacomp.2025.109193_bb0555","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/eurpub\/ckz034.070","article-title":"Body mass index and body composition in institutionalized older adults with malnutrition, sarcopenia and frailty","volume":"29","author":"Marques","year":"2019","journal-title":"Eur J Public Health"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725002466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725002466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T05:20:10Z","timestamp":1763788810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872725002466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":111,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1056872725002466"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109193","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Criteria of frail older people with type 2 diabetes who are suitable for SGLT-2 inhibitors and GLP-1RA therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"109193"}}